US Patent 8,951,969: Scope, Claims, Expiration, Orange Book Status, and Akynzeo Patent Landscape

US Patent 8,951,969 protects the fixed-dose oral combination of netupitant and palonosetron used in Akynzeo. Its strongest commercial coverage is directed to the marketed capsule architecture: three netupitant tablets and one palonosetron soft-gel capsule enclosed within a hard shell. The patent also covers pharmacokinetic effects, including faster netupitant absorption and increased exposure when palonosetron is co-administered.

The patent was assigned to Helsinn Healthcare SA and is associated with the US regulatory protection for Akynzeo, a netupitant/palonosetron product approved by the FDA for prevention of acute and delayed nausea and vomiting associated with highly emetogenic and moderately emetogenic cancer chemotherapy.[1,2]

What does US Patent 8,951,969 protect?

US 8,951,969 protects an oral dosage form containing approximately 300 mg of netupitant, measured as the free base, and approximately 0.56 mg of palonosetron hydrochloride.[3]

The claims divide into two principal categories:

Product and capsule-structure claims.
Pharmacokinetic and combination-effect claims.

Claim group	Protected subject matter	Commercial relevance
Claim 1	Oral dosage form containing about 0.56 mg palonosetron hydrochloride and about 300 mg netupitant free base	Covers the active-ingredient combination at the marketed strength
Claims 2-6	Multicomponent capsule containing three netupitant tablets and one palonosetron soft-gel capsule inside a hard outer shell	Closely tracks the Akynzeo capsule design
Claims 7 and 11	Combination that shortens median netupitant Tmax by about 0.5 hour	Protects a defined absorption-time result
Claims 8-10	Combination that increases netupitant AUC and, in narrower claims, Cmax and reduces Tmax	Protects pharmacokinetic interaction between the two drugs

The patent does not merely claim netupitant and palonosetron as active ingredients in any dosage form. It specifies dose levels, physical components, capsule permeability, soft-gel composition, impurity content and pharmacokinetic performance.

What are the key limitations of independent claims 1, 2, 7, and 8?

Claim 1: fixed-dose combination composition

Claim 1 requires an oral pharmaceutical dosage form comprising:

About 0.56 mg of palonosetron hydrochloride; and
About 300 mg of netupitant as the free base.

The claim is relatively broad as a product claim because it does not require the hard-shell capsule, three-tablet configuration or soft-gel presentation. A competing product containing the same active ingredients at materially equivalent amounts could potentially fall within the claim even if it used a different internal arrangement.

The terms "about" create a numerical range rather than an exact single-point limitation. The precise range would depend on claim construction, specification support and potentially prosecution history. A generic developer would need to assess whether its labeled strengths and manufacturing tolerances fall within the claim scope.

Claim 2: hard-shell capsule containing four internal units

Claim 2 is narrower and more structurally specific. It requires:

A hard outer capsule shell;
Three tablets, each containing approximately 100 mg of netupitant; and
One soft-gel capsule containing approximately 0.56 mg of palonosetron hydrochloride;
All four internal units housed within the hard outer shell.

This claim tracks a product architecture designed to combine a solid netupitant component with a liquid-filled or semisolid palonosetron component. A product using a conventional bilayer tablet, a single compressed tablet or two separate conventional capsules could avoid the literal structural limitations of claim 2 while remaining exposed to broader claims, particularly claim 1 or the pharmacokinetic claims.

Claim 7: shorter netupitant Tmax

Claim 7 covers a composition in which a single dose of netupitant and palonosetron produces a median netupitant Tmax approximately 0.5 hour shorter than a comparable dose of netupitant administered alone.

This is a result-oriented claim. It does not require the specific Akynzeo capsule structure or exact 300 mg/0.56 mg amounts. Its scope turns on the comparator composition, dosing conditions, statistical method and pharmacokinetic data used to establish the claimed difference.

Claim 8: increased netupitant AUC

Claim 8 requires a combination of netupitant and palonosetron that provides a greater netupitant AUC than the same amount of netupitant administered alone.

Claims 9-11 narrow claim 8 by requiring:

Greater netupitant Cmax;
Shorter netupitant Tmax; and
A median Tmax that is 0.5 hour shorter.

The pharmacokinetic claims can create infringement risk for a product with a different physical presentation if clinical or bioequivalence testing demonstrates the claimed exposure profile.

How do claims 2 through 6 protect the Akynzeo capsule design?

Claims 2 through 6 create a layered formulation position around the internal capsule components.

Claim	Additional limitation
2	Three 100 mg netupitant tablets and one palonosetron soft-gel capsule in a hard shell
3	Total dose of 300 mg netupitant and 0.56 mg palonosetron hydrochloride
4	Additional specified palonosetron-related compound at no more than 3 wt. %
5	Hard shell oxygen permeability below 1.0 × 10^-3 ml·cm/(cm²·24 hr·atm)
6	Soft-gel inner fill containing about 75% to 98% lipophilic components

Claim 4: impurity or related-compound limitation

Claim 4 limits the amount of the specified bicyclic quaternary compound to no more than 3 wt. %. The compound is structurally related to palonosetron and is treated in the claim as a controlled component or impurity.

This limitation can matter during ANDA review because a generic applicant must control related substances through raw-material specifications, manufacturing conditions, degradation studies and release testing. A product that reproduces the claimed formulation but exceeds the specified impurity threshold could avoid this dependent claim while remaining exposed to claims 1, 2, 3 or 7-11.

Claim 5: oxygen-barrier shell

Claim 5 requires a hard capsule shell with oxygen permeability below 1.0 × 10^-3 ml·cm/(cm²·24 hr·atm).

The limitation indicates that oxygen control is part of the formulation strategy. It may protect against oxidation or degradation affecting palonosetron, netupitant or excipients. A competing manufacturer could attempt to design around this limitation using a shell with higher oxygen permeability, a different packaging system, oxygen scavengers or a different dosage form. That approach would not necessarily avoid the broader combination claim in claim 1.

Claim 6: lipophilic soft-gel fill

Claim 6 requires the soft-gel capsule to have an inner fill containing approximately 75% to 98% by weight of one or more lipophilic components.

This limitation is relevant to the absorption of the poorly water-soluble active ingredient or to the stability and dispersion of palonosetron in the soft-gel component. A hard-shell capsule containing a liquid-filled insert with a substantially different excipient system could avoid claim 6 while still implicating claims 1-3 or the pharmacokinetic claims.

What is the likely patent expiration date for US 8,951,969?

US 8,951,969 has an Orange Book-listed expiration date of July 30, 2030.[2] The effective market-exclusivity date may be later if an applicable pediatric extension is granted and properly listed for the product.

Milestone	Date or status
US patent	8,951,969
Patent type	Utility patent
Patent holder	Helsinn Healthcare SA
Issued	January 27, 2015
Orange Book-listed expiration	July 30, 2030
Product associated with listing	Akynzeo capsules
Regulatory pathway for challengers	ANDA with Paragraph IV certification
Biosimilar pathway	Not applicable

Patent expiration does not automatically establish the first date on which a generic can launch. A generic applicant may launch before expiration if the patent is invalidated, found not infringed, disclaimed, removed from the Orange Book or resolved through a settlement agreement. Regulatory exclusivity, patent-term adjustments and pediatric exclusivity must also be evaluated separately.

What is the Orange Book status of US 8,951,969?

US 8,951,969 is associated with Akynzeo, the fixed-dose netupitant/palonosetron product approved under NDA 205718.[1,2] The listing provides an Orange Book basis for a patent certification in an ANDA directed to the protected product.

The relevant commercial distinction is between:

A generic seeking approval for the same fixed-dose combination and dosage form;
A generic using the same strengths but a different formulation or capsule architecture; and
A product containing only netupitant or only palonosetron.

The first category faces the clearest risk under claims 1-3. The second may avoid the narrower formulation claims but still face claim 1 and claims 7-11. Single-agent products do not practice the claimed combination, although separate administration of the two drugs could raise method-of-use or induced-infringement questions only if other patents and approved labeling support those theories.

Which related patents cover Akynzeo and the netupitant/palonosetron combination?

Akynzeo has been associated with a group of US patents covering the combination, formulation and related pharmaceutical technology.

US patent	General landscape role	Reported expiration
8,895,633	Related Akynzeo formulation or combination protection	July 30, 2029
8,951,969	Fixed-dose combination, capsule architecture and pharmacokinetic claims	July 30, 2030
9,018,311	Related combination or dosage-form protection	July 30, 2030
9,669,029	Follow-on formulation or pharmaceutical-composition protection	July 30, 2030
10,292,979	Later related patent protection	July 30, 2030

The precise infringement analysis requires claim-by-claim comparison because continuation and divisional patents can separate protection among active ingredients, dosage forms, excipient systems, manufacturing methods and pharmacokinetic outcomes. A generic product that avoids one listed patent may remain exposed to another.

How strong is the patent estate for netupitant and palonosetron?

The estate is commercially strong for the marketed presentation because it combines several claim types:

A fixed-dose composition claim.
A specific internal capsule configuration.
Dose-specific dependent claims.
Oxygen-barrier packaging or shell limitations.
Lipophilic soft-gel fill limitations.
Pharmacokinetic claims directed to increased AUC, increased Cmax and reduced Tmax.

This structure creates multiple potential infringement theories. A product can avoid the three-tablet/one-soft-gel configuration yet potentially fall within claim 1. Conversely, a product that uses the same architecture but produces materially different pharmacokinetic results may avoid some dependent claims while remaining exposed to the product claims.

The principal vulnerability is that claims 7-11 depend on comparative pharmacokinetic outcomes. Their enforceability may turn on:

How "same amount of netupitant alone" is defined;
Whether the comparator must use the same excipients and dosage form;
Whether "about 0.5 hour" has adequate support;
Whether the specification enables the full claimed range;
Whether prior art disclosed the same combination and pharmacokinetic effect; and
Whether the measured result is inherent in a prior-art formulation.

Claims 1-6 are more conventional product and formulation claims. Their strength will generally depend on literal structural comparison and the treatment of "about" in the dose limitations.

What Paragraph IV challenges could target US 8,951,969?

An ANDA applicant seeking approval of a generic Akynzeo product could submit a Paragraph IV certification alleging that the patent is invalid, unenforceable or not infringed. Potential challenge positions include:

Noninfringement

A challenger could use:

A different dosage form;
A single tablet instead of three netupitant tablets;
A conventional capsule rather than a soft-gel insert;
A shell that does not meet the oxygen-permeability limitation;
A soft-gel fill outside the claimed lipophilic range; or
A formulation that does not produce the claimed pharmacokinetic result.

Invalidity

Potential validity attacks could rely on:

Anticipation by earlier netupitant/palonosetron combination disclosures;
Obviousness based on combining known NK1 antagonists and 5-HT3 antagonists;
Obvious selection of the 300 mg/0.56 mg dose combination;
Lack of enablement across the claimed dosage and PK scope;
Indefiniteness of "about," "greater AUC," "shorter Tmax" or the comparator language; and
Written-description issues for broad pharmacokinetic claims.

Regulatory timing

A Paragraph IV notice can trigger a 45-day period for the patent owner or NDA holder to file an infringement action. A timely action can produce a 30-month stay of final FDA approval under the Hatch-Waxman Act, subject to court decisions and statutory exceptions.[4]

No biosimilar pathway applies because Akynzeo is a small-molecule drug. Generic competition would proceed through the ANDA process, not the abbreviated pathway for biological products.

What generic launch scenarios exist for Akynzeo?

Launch scenario	Principal condition
At patent expiration	ANDA approval with all blocking patents expired or otherwise resolved
At-risk launch	Generic launches while patent litigation remains pending
Settlement launch	Parties agree to a negotiated date, license or other commercial terms
Non-infringing formulation	Generic obtains approval with a dosage form designed to avoid asserted claims
Patent invalidation	Court or PTAB decision removes the relevant barrier
Carve-out strategy	Label omits a patented use, if the approved indication and claim scope permit

The most difficult path is a generic that reproduces the Akynzeo capsule exactly. Such a product would likely face claims 1-3 and could also implicate claims 5 and 6. A redesigned product could reduce structural risk but would need to address the broad composition and pharmacokinetic claims.

What litigation or settlement issues affect the patent?

Patent litigation risk centers on ANDA filings, Paragraph IV notices, claim construction and settlement terms. Public FDA patent listings establish the regulatory patent position, but they do not by themselves establish whether a specific generic applicant has challenged the patent.

A litigation assessment should distinguish among:

The patent listed for the reference product;
The claims asserted in a complaint;
The claims surviving claim construction or summary judgment;
Any covenant not to sue;
Any agreed generic-entry date;
Authorized-generic arrangements; and
Whether a settlement was submitted to the Federal Trade Commission under applicable pharmaceutical settlement reporting rules.

The available patent and FDA materials identify the patent estate and product relationship. They do not establish a universal generic launch date for every possible formulation design.

How does US 8,951,969 compare with ordinary combination-product patents?

US 8,951,969 is broader than a single formulation patent but narrower than a pure active-ingredient genus patent.

Patent type	Typical scope	Relation to US 8,951,969
Active-ingredient patent	Covers a compound or broad chemical class	8,951,969 does not claim netupitant alone
Fixed-dose combination patent	Covers two active ingredients at defined strengths	Claim 1 is a strong example
Formulation patent	Covers excipients, dosage form or release properties	Claims 2-6 provide this layer
Method-of-use patent	Covers treatment or prevention of a condition	The stated claims are dosage-form and PK claims, not direct treatment claims
PK or drug-interaction patent	Covers a measured exposure or absorption result	Claims 7-11 provide this layer
Manufacturing patent	Covers a process or production method	The stated claims do not directly claim manufacturing

The patent is most valuable when the commercial product uses the claimed combination and capsule construction. Its PK claims expand the risk beyond the precise marketed architecture but may present greater litigation complexity.

Key Takeaways

US 8,951,969 covers the netupitant/palonosetron fixed-dose combination at approximately 300 mg and 0.56 mg, respectively.
Claim 2 closely tracks the Akynzeo capsule: three 100 mg netupitant tablets and one palonosetron soft-gel capsule inside a hard shell.
Claims 5 and 6 protect oxygen-barrier shell properties and a lipophilic soft-gel fill.
Claims 7-11 protect increased netupitant exposure and faster absorption when palonosetron is included.
The reported Orange Book expiration date is July 30, 2030.
Generic competition would proceed through Hatch-Waxman ANDA litigation, not biosimilar review.
A redesigned generic may avoid the narrower capsule claims but still face claim 1 and the pharmacokinetic claims.
The patent estate includes related US patents that may preserve blocking positions even if a challenger avoids or invalidates one patent.
The principal commercial exposure is concentrated in a generic that duplicates the marketed Akynzeo composition and capsule architecture.

FAQs

Does US 8,951,969 cover netupitant by itself?

No. The claims require netupitant together with palonosetron, or a dosage form containing both agents.

Does changing the three netupitant tablets to one tablet avoid the patent?

It may avoid the specific architecture in claim 2, but it does not necessarily avoid claim 1 or claims 7-11.

Is Akynzeo protected by a biologic exclusivity period?

No. Akynzeo is a small-molecule fixed-dose combination. Its generic pathway is an ANDA, not a biosimilar application.

Can a generic use the same active ingredients at different strengths?

A materially different strength may avoid the dose-specific limitations, but infringement would depend on the meaning of "about" and the scope of other listed patents.

Does the patent claim treatment of chemotherapy-induced nausea and vomiting?

The stated claims primarily cover dosage forms, composition features and pharmacokinetic outcomes. They do not directly recite a treatment method for chemotherapy-induced nausea and vomiting.

References

U.S. Food and Drug Administration. (2014). Akynzeo (netupitant and palonosetron) prescribing information. FDA.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Patent and Trademark Office. (2015). U.S. Patent No. 8,951,969: Pharmaceutical composition comprising netupitant and palonosetron. U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Amendments. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes	8,951,969	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3083	⤷ Start Trial
Australia	2010320598	⤷ Start Trial
Brazil	112012011485	⤷ Start Trial
Canada	2778301	⤷ Start Trial
Chile	2012001276	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,951,969

Which drugs does patent 8,951,969 protect, and when does it expire?

Summary for Patent: 8,951,969